Alternatives to Longevixx

A multi-category telehealth shop with some of the lowest disclosed GLP-1 starting prices in this batch — from $99/mo semaglutide, $140/mo tirzepatide — though the site's own disclosure that pricing 'may vary' means the real ongoing cost isn't fully locked in.

One of the lowest disclosed GLP-1 starting prices in this round — from $99/mo semaglutide, $133/mo tirzepatide — with an explicit no-membership, no-hidden-fee claim, though the real ongoing rate at a working dose isn't confirmed.

Both prices came down since our last check — read live on 2026-08-26 the product cards say compounded semaglutide from $99 a month and tirzepatide from $199, against $149 and $224 in mid-August, with microdose versions at $119 and $139 beside them. Still "from", and Medro is unusually candid about what that means: its own FAQ says starting-at pricing "reflects the lowest typical option" and that final cost varies by medication, dose, supply duration, partner pricing, availability and eligibility, while a footnote under the cards calls the pricing "illustrative". Two other things this record used to get wrong. The site does name its operating entity, Medro Health Technologies, Inc., in the Refund Policy, along with its clinical partner Arora Health & Aesthetics in Seattle and its pharmacy partner The Pharmacy Hub in Miami. And it does publish a cancellation policy — one that sits awkwardly against the FAQ, because the FAQ says there is no membership and nothing recurring to cancel while the Refund Policy describes a subscription charged the moment you finish the intake form, needing 72 hours' notice to stop, with no refund on cancellation.

Flat-rate pricing with a real dietitian included ($119/mo semaglutide, from $175/mo tirzepatide) from a nine-year-old operator — carrying an open FDA warning letter over how it described its own compounded products.

A named-Medical-Director program licensed in all 50 states, from $99/mo semaglutide and $183/mo tirzepatide, with no membership required — but it carries a 2025 FDA warning letter over how it described its compounded medication, and both prices are 'From' starting prices rather than a guaranteed working-dose rate.

$99 semaglutide, $149 tirzepatide, flat at every dose, all 50 states. Renewal prices match advertised prices in the checkout data, so the no-price-rise claim holds. A plan month is four weeks; the '12-month' plan at $999 is 48 weeks. Same operator as Lean Meds, altRx and NextMeds — one company, four storefronts — and that operator holds FDA letter 728236, still open.

For a working mother the appeal here is logistics as much as money: a fully online intake with no video call to schedule, all 50 states, and one flat charge per month that covers the visit, the plan, the medication and shipping — held at the same price whatever dose you end up on. Month to month that is $79 for compounded semaglutide and $109 for compounded tirzepatide; the $69 the homepage headlines under a countdown timer is the twelve-month tier, and $95 is its tirzepatide equivalent. Flat-by-dose is the part that actually protects a budget, because dose-priced providers routinely double between a starting and a maintenance dose. Two things to weigh against that. The off-ramp is narrow: subscriptions auto-renew, canceling means emailing care@leanmeds.com at least 48 hours before the processing date, and the order stops being refundable the moment you submit the medical intake. And the operator named throughout its own Terms — Trinity HealthCare Supply, LLC — is the company FDA wrote to on 8 June 2026 under its other brand, altRx, for labeling compounded vials with its own name when it was not the compounder and for calling compounded GLP-1s 'clinically proven.' That letter concerns altrx.com, not this site, but it is the same legal entity at the same Miami suite, and no pharmacy or clinician is named here either.

FDA warning letter #721472 (Feb. 2026), which names newself.com. A flat, dose-independent price for both molecules — $99.97/mo semaglutide, $144.49/mo tirzepatide, same price at every dose — nationwide, though it requires 3 months upfront.

Compounded semaglutide at $79 a month and tirzepatide at $119, month to month, with no dose-based increase and — checked in its own checkout data rather than taken on trust — a renewal price identical to the joining price. That last part is rarer than it should be. Two things the homepage will not tell you. The $49 and $99 it advertises are the twelve-month totals divided by twelve, not a monthly rate you can start on, and the countdown beside them is not a real deadline: it read August 15th and then August 20th within the same hour. The larger caveat is corporate. NextMeds is operated by Trinity HealthCare Supply, LLC, which also runs Lean Meds, altRx and Trinity Meds, and that operator holds an open FDA warning letter.